for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Vera Therapeutics Inc

VERA.OQ

Latest Trade

35.99USD

Change

0.19(+0.53%)

Volume

3,467

Today's Range

35.87

 - 

37.00

52 Week Range

11.35

 - 

37.00

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
35.80
Open
36.00
Volume
3,467
3M AVG Volume
1.69
Today's High
37.00
Today's Low
35.87
52 Week High
37.00
52 Week Low
11.35
Shares Out (MIL)
21.28
Market Cap (MIL)
638.33
Forward P/E
-11.70
Dividend (Yield %)
--

Latest Developments

More

Vera Therapeutics Reports Third Quarter 2021 Financial Results

Vera Therapeutics Reports Second Quarter 2021 Financial Results

Vera Therapeutics - Q1 Loss Per Share $12.23

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Vera Therapeutics Inc

Vera Therapeutics, Inc. is a clinical stage biotechnology company. The Company is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a biologic inhibitor of B cells and plasma cells. Atacicept is self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL), which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases. Atacicept is being developed for the treatment of immunoglobulin A nephropathy (IgAN), a rare autoimmune disease that can lead to dialysis, kidney transplant, serious disease and early death.

Industry

Business Services

Contact Info

170 Harbor Way, 3rd Floor

SOUTH SAN FRANCISCO, CA

94080

United States

+1.650.7700077

https://veratx.com/

Executive Leadership

Marshall Fordyce

Chief Executive Officer, Founder, Director

Sean P. Grant

Chief Financial Officer

Tom Doan

Senior Vice President - Clinical Operations & Clinical Data Management

Joanne Curley

Chief Development Officer

Lauren Frenz

Chief Business Officer

Key Stats

1.67 mean rating - 3 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2021(E)

0.0K
EPS (USD)

2021(E)

-2.563
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
7.47
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
--
Return on Equity (TTM)
--

Latest News

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up